Get the Stockscreener App
0.2179
13.57%
-0.2022
Avenue Therapeutics Inc stock is traded at $0.2179, with a volume of 1,126.
It is down -13.57% in the last 24 hours and down -70.96% over the past month.
See More
Previous Close:
$0.42
Open:
$0.21785
24h Volume:
1,126
Relative Volume:
66.00
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-10.38M
P/E Ratio:
-0.0572
EPS:
-3.81
Net Cash Flow:
$-12.45M
1W Performance:
-13.57%
1M Performance:
-70.96%
6M Performance:
-83.79%
1Y Performance:
-96.88%
1-Day Range:
$0.2179
$0.2179
1-Week Range:
$0.2179
$0.2179
52-Week Range:
$0.2179
$0.2179
Avenue Therapeutics Inc Stock (ATXI) Company Profile
Name
Avenue Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare ATXI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATXI
Avenue Therapeutics Inc
|
0.2179 | 0 | 0 | -10.38M | -12.45M | -3.81 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Avenue Therapeutics Inc Stock (ATXI) Latest News
Wall Street Analysts Predict a 310.96% Upside in Candel Therapeutics (CADL): Here's What You Should Know - MSN
Annji Pharmaceutical Company Announces Positive Phase 1/2A Results for Aj201 in Spinal and Bulbar Muscular Atrophy Patients - marketscreener.com
Avenue Therapeutics stock hits 52-week low at $1.5 amid challenges - MSN
Avenue Therapeutics Ends License Agreement with AnnJi - TipRanks
Form DEF 14A PALVELLA THERAPEUTICS, For: Jun 10 - StreetInsider
Form DEFC14A ZEVRA THERAPEUTICS, INC. Filed by: ZEVRA THERAPEUTICS, INC. - StreetInsider
Pre-market Movers: RGC, SYRS, ADTX, ATXI... - RTTNews
CBLI Back On Track, HTBX Joins Hands With OncoSec, PRAH In Good Health - RTTNews
Drug Resistant Epilepsy Market reached US$ 0.78 billion in 2022 - openPR.com
SEC Form POS AM filed by Fortress Biotech Inc. - Quantisnow
AVENUE THERAPEUTICS, INC. SEC 10-K Report - TradingView
Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
Fortress Biotech Transforms Portfolio: Dual FDA Wins, $28M Deal, Latest Earnings - Stock Titan
Oncotelic Therapeutics Publishes New Research Demonstrating Positive Prognostic Impact of Methylated TGFB2 and MGMT in Adult Glioblastoma Patients, Introduces Interactive PDAOAI - The Manila Times
Oncotelic Therapeutics Publishes New Research Demonstrating - GlobeNewswire
North American Morning Briefing : Tariff Jitters -2- - Marketscreener.com
Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals Stocks - The Globe and Mail
eXp World (EXPI): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail
1 Technology ETF to Buy Hand Over Fist and 1 to Avoid - The Globe and Mail
North American Morning Briefing : Stock Futures Fall as Focus Shifts From Fed to Tariffs - Marketscreener.com
Biotech Alert: Searches spiking for these stocks today - TipRanks
Dassault Systèmes Intensifies the MEDIDATA Commitment to Patient Experience With Investment in Click Therapeutics for Digital Therapeutics Beyond Clinical Trials - Yahoo Finance
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.62% - Investing.com
United States shares lower at close of trade; Dow Jones Industrial Average down 0.62% - Investing.com India
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Dow Dips Over 200 Points; US Industrial Production Increases More than Expected - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - Benzinga India
Avenue Therapeutics, Inc. (NASDAQ:ATXI) Sees Large Decline in Short Interest - Defense World
Atlanticus Holdings Co. 9.25% Senior Notes due 2029 (NASDAQ:ATLCZ) Short Interest Update - Defense World
AVENUE THERAPEUTICS Earnings Preview: Recent $ATXI Insider Trading, Hedge Fund Activity, and More - Nasdaq
Avenue Therapeutics Inc expected to post a loss of 57 cents a shareEarnings Preview - TradingView
Postoperative Pain Clinical Pipeline | 45+ Companies, - openPR
Avenue Therapeutics stock hits 52-week low at $0.9 amid downturn - Investing.com India
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Episode 203Curtis Oltmans - Audacy
Beam Therapeutics Announces Pricing of Underwritten Offering - GlobeNewswire
Avenue Therapeutics granted Nasdaq extension, faces AnnJi dispute By Investing.com - Investing.com South Africa
Avenue Therapeutics granted Nasdaq extension, faces AnnJi dispute - Investing.com India
Avenue Therapeutics Annji Intends To Terminate License Agreement With Co -March 07, 2025 at 04:36 pm EST - Marketscreener.com
Intra-Cellular deal, Axsome settlement drive neurological index recovery - BioWorld MedTech
Wall Street Analysts Believe Keros Therapeutics (KROS) Could Rally 153.67%: Here's is How to Trade - Nasdaq
New version of Merck's Keytruda faces possible patent battle, WSJ reports - Reuters
SEC Form 424B5 filed by Y-mAbs Therapeutics Inc. - Quantisnow
Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Down 40.5% in February - Defense World
BriaCell Therapeutics Corp. (NASDAQ:BCTX) Sees Significant Increase in Short Interest - Defense World
KESTRA MEDICAL TECHNOLOGIES, LTD. Prices IPO at $14.00-$16.00 Per Share (KMTS) - Defense World
Short Interest in ArrowMark Financial Corp. (NASDAQ:BANX) Expands By 62.6% - Defense World
American Rebel Holdings, Inc. (NASDAQ:AREB) Sees Large Growth in Short Interest - Defense World
Arbe Robotics Ltd. (NASDAQ:ARBE) Short Interest Up 56.5% in February - Defense World
PTC Therapeutics (NASDAQ:PTCT) Shares Gap Down After Analyst Downgrade - Defense World
Avenue Therapeutics Inc Stock (ATXI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Cap:
|
Volume (24h):